Dr Koster @MdWarrington @AliDuarteMD open label study baricitinib in relapsing GCA. Well-tolerated and allowed GC discontinuation by 24 weeks in most patients. Encouraging, we need an RCT! Abstr#1396 #ACR21 @RheumNow https://t.co/N2h54MHpIq

FDA update: Voclosporin Safety in #SLE RCTs #ACR21 https://t.co/xWCBELxQIc

FDA Safety Update - Dr. Nadia Habal reviewed approval of Voclosporin, anifrolumab, Avacopen and approved new indications for multiple drugs #ACR21 https://t.co/lAgQ4d0h2m

FDA safety update: OA Stakeholder Workshop June 2021 - Congrats to FDA & AFfor tackling this LARGE unmet need- difficulty in determining benefit in OA (pain, structure, biomarkers?) -more research needed #ACR21 https://t.co/hCWU8OL0Le

FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19: 1. RECOVERY - lower mortality 2. EMPACTA - Less progression to mech vent or death 3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej

FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH

FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically important during COVID-19) Session 8M115 https://t.co/DqmxEIdvWZ D https://t.co/6aQG8yP7RW

• https://bit.ly/301fOvh

#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC: ⬇️Titres of Abs in SLE vs controls 💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA 📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9

• Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Pa…

Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5

"Managing comorbidities can really improve outcomes for our patients" @UnaMakris highlights the bio-psycho-social approach to multicomplexity and multimorbidity in our older patients with RA. #ACR21 @RheumNow https://t.co/TMLqoreogZ

#ACR21 Gift of Gab https://t.co/R1e14UA0pQ Change habits through your words ⭐️Cost of inaction ⭐️Incremental change (ex ⬇️EtOH) ⭐️Follow the crowd! ⭐️Why not try? Good advice for persuading pts re behavior change, Rx adherence, smoking cessation, vax hesitancy, etc. @Rheumnow https://t.co/9Cd7hAafTr

• https://bit.ly/3BVZR6D

Pain can affect so many aspects of life; Dr. @unamakris noted that pain in older adults increase risk for: 👉falls/fracture 👉depression/anxiety 👉suicide 👉impaired nutrition 👉sleep disturb 👉mobility issues 👉cognitive deficits 👉frailty 👉spousal distress #ACR21 @rheumnow https://t.co/LicBiTRRKn

This is a reassuring introduction to Dr. Janet Zeide's lecture on the Gift of Gab! 😊 Might need to remind myself of this more regularly😉 @RheumNow #ACR21 @rheumarhyme #publicspeaking https://t.co/AoOmFkQUBk

Study on enthesitis response to biologic Rx ⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab ⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab 🔰Superiority of TNFi versus secukinumab in regards to active enthesitis Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ

Really love this slide from @UnaMakris on the "5Ms of #Ageing"- will be trying to apply this in the clinical setting. 📊#Multicomplexity 🧠#Mind 🚶#Mobility 💊#Medications 🎯#WhatMattersMost #ACR21 @RheumNow https://t.co/bCQN4VpyBP